Pier Paolo Scaglioni, MD, is a clinician researcher that specializes in benign hematology with a focus on leukemia.
Much of Scaglioni’s research efforts focus on how specific genes can be manipulated to stunt cancer cell growth and on running clinical trials for new cancer drugs. Dr. Scaglioni leads a laboratory team that is studying the effect of K-RAS in non-small cell lung cancer. They have found that K-RAS regulates the metabolism of fatty acids to make the complex lipids necessary for cell proliferation and that K-RAS also helps cells replace fatty acids that are damaged by free radicals.
Dr. Scaglioni is currently working to build integrated scientific programs between the UC College of Medicine and Cincinnati Children's, in order to build a pipeline from the basic discoveries to eventually, the patients.
Dr. Scaglioni’s responsibilities as Division Director include increasing the department’s research efforts by adding more scientists, cancer biologists and physician scientists to his team to boost the college’s focus on cancer research.
Early in his career, Dr. Scaglioni was awarded the Young Investigator’s Award, by the American Society of Clinical Oncology, and in 2013, he was awarded Friend’s Award in Cancer Research, by the Friends of the Comprehensive Cancer Center.